Literature DB >> 11020863

Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer.

S Bekku1, H Mochizuki, T Yamamoto, H Ueno, E Takayama, T Tadakuma.   

Abstract

BACKGROUND/AIMS: This study was undertaken to elucidate the correlation between the expression of carbonic anhydrase I or II and the characteristic features of colorectal cancer.
METHODOLOGY: The carbonic anhydrase I or II expressions of 74 colorectal cancer patients were analyzed by Western blotting. The relative intensity of cancer to the paired normal mucosa was calculated, and then compared with the clinicopathological parameters. Furthermore, a multivariate analysis for synchronous distant metastasis was undertaken.
RESULTS: The expression of carbonic anhydrase I in colon cancer or carbonic anhydrase II in rectal cancer with Duke's D was found to be significantly lower than that with Duke's B or C, respectively. Similarly, carbonic anhydrase I in colon cancer or carbonic anhydrase II in rectal cancer with moderate-severe budding was found to be significantly lower than that with none-mild budding, respectively. Based on the findings of a logistic regression analysis, carbonic anhydrase I was adopted for colon cancer (P = 0.057) and carbonic anhydrase II for rectal cancer (P = 0.008) regarding synchronous distant metastasis.
CONCLUSIONS: The expressions of carbonic anhydrase I and II correlated with biological aggressiveness of colorectal cancer and synchronous distant metastasis, especially carbonic anhydrase I for colon cancer and carbonic anhydrase II for rectal cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11020863

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  14 in total

1.  HFIP extraction followed by 2D CTAB/SDS-PAGE separation: a new methodology for protein identification from tissue sections after MALDI mass spectrometry profiling for personalized medicine research.

Authors:  Rémi Longuespée; Christophe Tastet; Annie Desmons; Olivier Kerdraon; Robert Day; Isabelle Fournier; Michel Salzet
Journal:  OMICS       Date:  2014-05-19

2.  Generation of an inducible colon-specific Cre enzyme mouse line for colon cancer research.

Authors:  Paul W Tetteh; Kai Kretzschmar; Harry Begthel; Maaike van den Born; Jeroen Korving; Folkert Morsink; Henner Farin; Johan H van Es; G Johan A Offerhaus; Hans Clevers
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-05       Impact factor: 11.205

3.  Ldb1 regulates carbonic anhydrase 1 during erythroid differentiation.

Authors:  Sang-Hyun Song; Aeri Kim; Ryan Dale; Ann Dean
Journal:  Biochim Biophys Acta       Date:  2012-05-18

4.  A new prognostic staging system for rectal cancer.

Authors:  Hideki Ueno; Ashley B Price; Kay H Wilkinson; Jeremy R Jass; Hidetaka Mochizuki; Ian C Talbot
Journal:  Ann Surg       Date:  2004-11       Impact factor: 12.969

Review 5.  Searching for consistently reported up- and down-regulated biomarkers in colorectal cancer: a systematic review of proteomic studies.

Authors:  Yanlei Ma; Peng Zhang; Feng Wang; Huanlong Qin
Journal:  Mol Biol Rep       Date:  2012-06-15       Impact factor: 2.316

6.  M2PP: a novel computational model for predicting drug-targeted pathogenic proteins.

Authors:  Shiming Wang; Jie Li; Yadong Wang
Journal:  BMC Bioinformatics       Date:  2022-01-04       Impact factor: 3.169

7.  Tip60 might be a candidate for the acetylation of hepatic carbonic anhydrase I and III in mice.

Authors:  Nurdan Gönül Baltacı; Enver Fehim Koçpınar; Harun Budak
Journal:  Mol Biol Rep       Date:  2021-10-15       Impact factor: 2.316

Review 8.  The Role and Interactions of Programmed Cell Death 4 and its Regulation by microRNA in Transformed Cells of the Gastrointestinal Tract.

Authors:  William Frank Ferris
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

9.  Enhancing the Anticancer Potential of Targeting Tumor-Associated Metalloenzymes via VEGFR Inhibition by New Triazolo[4,3-a]pyrimidinone Acyclo C-Nucleosides Multitarget Agents.

Authors:  Mohamed Nabil Abd Al Moaty; El Sayed Helmy El Ashry; Laila Fathy Awad; Nihal Ahmed Ibrahim; Marwa Muhammad Abu-Serie; Assem Barakat; Mezna Saleh Altowyan; Mohamed Teleb
Journal:  Molecules       Date:  2022-04-08       Impact factor: 4.927

10.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Vincenzo Costigliola; Daniela Trog; Michael Braun; Manuel Debald; Walther Kuhn; Hans H Schild
Journal:  EPMA J       Date:  2013-02-19       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.